Lotus Pharmaceutical became an Alvogen Company in 2014. The company deploys its state-of-the-art internal development and manufacturing capabilities spanning Taiwan and South Korea to benefit all of its stakeholders – patients, employees and shareholders alike. Leveraging its direct relationships with Alvogen’s commercial units in over 30 countries and through alliances with top-tier pharma companies, Lotus' products can reach patients in nearly every global market.

Lotus Pharmaceutical’s growth has been driven by its focus on producing and marketing a unique portfolio of high quality and difficult-to-make pharmaceutical products. Its ability to do so highly efficiently means that it can offer these generic medications at affordable prices, helping to reduce healthcare costs in all of the markets it participates in around the world. Lotus has more than 250 marketed products and more than 100 strategically selected pharmaceutical projects in development and registrations across Asia and the US.

Additionally, Lotus Pharmaceutical markets a growing portfolio of over-the-counter (OTC) medications and has partnered with Alvotech, another member of the Alvogen family, to market Alvotech's biosimilars products in Asian markets as soon as they are approved.

Lotus Pharmaceutical’s leadership team is dedicated to fostering a dynamic, change-driven culture committed to meeting the needs of its customers. Its organizational structure is lean and flexible, driving quick and effective decision making and enabling the company to advance a pipeline of safe and effective generics medicines swiftly to market.